Duchenne Muscular Dystrophy Gets a Boost with Sare..

Yeni bir makale oluşturdu

37 hafta

Duchenne Muscular Dystrophy Gets a Boost with Sarepta’s ELEVIDYS Approval | #duchenne muscular dystrophy # Duchenne muscular dystrophy Market # Duchenne muscular dystrophy Forecast # Duchenne muscular dystrophy Companies # Duchenne muscular dystrophy Drugs # Duchenne muscular dystrophy Therapies # Duchenne muscular dystrophy Epidemiology # Duchenne muscular dystrophy Pipeline # Duchenne muscular dystrophy Market Size # Duchenne muscular dystrophy Market Trends

Duchenne Muscular Dystrophy Gets a Boost with Sarepta’s ELEVIDYS Approval

The approval of ELEVIDYS (delandistrogene moxeparvovec-rokl) marks a new milestone in the fight against Duchenne Muscular Dystrophy (DMD). Developed by Sarepta Therapeutics, ELEVIDYS is the first gene therapy for DMD to receive FDA approval, offering hope to patients and families facing th

Beğen

Yorum yap

Paylaş

37 hafta

Duchenne Muscular Dystrophy Gets a Boost with Sarepta’s ELEVIDYS Approval

Dil